Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08WII
|
|||
| Drug Name |
Anti-MUC1 CAR T Cells
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1/2 | [1] | |
| Hepatocellular carcinoma [ICD-11: 2C12.02; ICD-10: C22.0; ICD-9: 155] | Phase 1/2 | [1] | ||
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 1/2 | [1] | ||
| Company |
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | CAR-T-Cell-Therapy | [1] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.